CenterBook Partners’s Indivior Pharmaceuticals INDV Stock Holding History

CenterBook Partners’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$240K	Sell	5,857 -42,645	-88%	-$1.55M	0.01%	655
2026 Q1	$1.48M	Sell	48,502 -19,577	-29%	-$647K	0.08%	285
2025 Q4	$2.44M	Sell	68,079 -41,380	-38%	-$1.26M	0.12%	230
2025 Q3	$2.64M	Sell	109,459 -12,213	-10%	-$256K	0.13%	218
2025 Q2	$1.79M	Sell	121,672 -127,754	-51%	-$1.49M	0.1%	240
2025 Q1	$2.38M	Sell	249,426 -898,415	-78%	-$9.45M	0.15%	174
2024 Q4	$14.3M	Buy	1,147,841 +589,158	+105%	+$6.06M	0.85%	21
2024 Q3	$5.45M	Buy	+558,683	New	+$6.54M	0.33%	86

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CenterBook Partners's INDV Position: Q2 2026 in Review

CenterBook Partners reduced its Indivior Pharmaceuticals (INDV) stake by 88% in Q2 2026, selling an estimated $1.55M and leaving 5,857 shares worth $240K. The position accounts for 0.01% of the portfolio, ranked #655.

CenterBook Partners first reported a position in INDV in Q3 2024 and has held it in 8 quarters since. The position peaked at $14.3M in Q4 2024. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

CenterBook Partners held 5,857 shares of Indivior Pharmaceuticals worth $240K as of Q2 2026.
CenterBook Partners sold 42,645 Indivior Pharmaceuticals shares in Q2 2026, an estimated $1.55M.
Indivior Pharmaceuticals made up 0.01% of CenterBook Partners's portfolio in Q2 2026, its #655 holding.
CenterBook Partners first reported a position in Indivior Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
CenterBook Partners's Indivior Pharmaceuticals position peaked at $14.3M in Q4 2024.
338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.